Replies to post #163533 on Anavex Life Sciences Corp (AVXL)

[OFP]

The Sarepta case was a one of a kind situation with very special circumstances. Jury is still out on whether it was a good decision or not. Anyone trying to use that as a precedent or model for FDA actions for anything but the most rare of diseases is going to be sorely disappointed (IMO).